Introduction
============

Metabolic syndrome (MetS) is a cluster of the most dangerous heart attack risk factors: diabetes and raised fasting plasma glucose (FPG), abdominal obesity, high cholesterol and high blood pressure (BP) ([@R1],[@R2],[@R3]). MetS is a major health problem worldwide; it is estimated that around 20 to 25 percent of the world\'s adult population have MetS, and mortality rate in these people is twice as likely from heart attack, and three times as likely from stroke compared with people without MetS ([@R4]). The underlying causes of the MetS have been suggested as central obesity and insulin resistance ([@R5],[@R6]). In addition, genetics, physical inactivity, ageing, proinflammatory state and hormonal changes may also have causal effects, but the role of these may vary depending on ethnic groups ([@R7],[@R8]). Physical inactivity is an independent risk factor for chronic diseases which is estimated to cause 1.9 million deaths, globally ([@R9],[@R10],[@R11]). Moreover, physical inactivity is considered as the fourth leading risk factor for global mortality causing an estimated 3.2 million annual deaths (6% of global deaths) ([@R12]). Physical activity (PA) decreases the risk for premature death, coronary artery disease, obesity, diabetes, hypertension (HTN), cancer and depression thereby lowering medical and medication costs and improving quality of life ([@R13]). The fact that the lack of PA and MetS is cardiovascular risk factors that increase overall morbidity makes the study of their interrelationships extremely important. Moreover, low levels of PA are strongly associated with the development of MetS and chronic diseases. To the best of our knowledge, this is the first study, which examined this association among type 2 diabetes mellitus (T2DM) patients in Gaza Strip, Palestine. the study was conducted to evaluate the association between PA and the MetS among T2DM patients in Gaza Strip, Palestine, and to examine the association between PA and diabetes complications.

Materials and Methods
=====================

**Study design and sampling technique**: This cross-sectional study was conducted in the years 2015 and 2016 among a representative sample of Palestinian T2DM patients, selected through cluster random sampling method. A total of 1200 patients (from both gender, aged 20 to 64 years) receiving care in the primary health care centers (PHCs) in Gaza Strip, Palestine, were included in the study. Gaza Strip is divided into five smaller governorates, which include North Gaza, Gaza City, Mid Zone, Khan Younis and Rafah. The total number of PHCs in Gaza Strip is fifty-four ([@R14]). The PHCs were distributed in each governorate as follows (eight, fourteen, sixteen, eleven and five respectively). The study sample was distributed according to the number of PHCs in each governorate as follows (178, 311, 356, 244 and 111 patients respectively). Pregnant women, lactating women and patients with other types of serious illness such as cancer, acute myocardial infarction or end stage kidney disease were excluded from the study.

**Assessment of blood pressure and anthropometric measures**: BP was measured from the left arm (mmHg), by mercury sphygmomanometer, three readings on different days. While the patient was seated after relaxing for at least 15 minutes in a quiet environment, empty bladder. The average of three measurements was recorded. Weight was measured with the use of a Seca scale and recorded to the nearest 0.1 kg. Height was measured with a Seca studiometer while subjects were standing with their shoulders positioned normally. The body mass index (BMI) was calculated as the weight in kilograms divided by the height in meters square. Waist circumference (WC) was measured at the narrowest level between the lowest rib and the iliac crest with the use of an outstretched tape measure. Measurements were recorded to the nearest 0.5 cm. After calculating BMI, individuals were categorized into underweight, healthy weight, overweight and obese using WHO cut-off point ([@R15]).

**Assessment of biomarkers**: After 12 hours fasting, a venous blood samples was collected from all patients in the primary health care centers (in the second meeting with the patients), by well-trained and experienced nurses. Venous blood (4.0 ml) was drawn into vacationer tubes and was used for blood chemistry analysis. Serum was separated immediately and the extracted serum was investigated for (FPG mg/dl, High Density Lipoprotein cholesterol (HDL-c) mg/dl and triglycerides (TGs) mg/dl). Mindray BS-300 chemistry analyzer instrument was used for blood chemistry analysis. The laboratory tests were analyzed in private licensed laboratory.

**Assessment of other variables**: Data on PA were obtained using the International Physical Activity Questionnaire (IPAQ short version) ([@R16]). The internationally accepted protocol was used to estimate the weekly calorie expenditure expressed as metabolic equivalents per week (MET/wk) or converted to kcal/wk using the formula kcal = MET × weight ÷ 60. The IPAQ scoring protocol assigns the following MET values to walking, moderate and vigorous intensity activity: 3.3 METs, 4.0 METs, and 8.0 METs, respectively. According to the IPAQ scoring protocol, the patients were classified based on their weekly energy expenditure as follows: Insufficiently Active (IA) ≤600 MET/wk; Sufficiently Active (SA) 601 to 1500 MET/wk; and Very Active (VA) ≥1500 MET/wk ([@R17]). Additional covariate information regarding age, medical history and diabetes complications was obtained with an interview-based questionnaire. Before the data collection, pilot study was carried out on thirty patients to enable the researcher to examine the tools of the study. The questionnaire and the data collection process were modified according to the result of the pilot study. The data was collected by ten qualified data collectors who were given explanation and training by the researcher about the study, its purpose, objectives, procedures and ways of distributing and collecting the questionnaire with respect to confidentiality.

**Definition of MetS**: MetS was defined according to the International Diabetes Federation (IDF) definition ([@R2]).

**Statistical analysis**: All statistical analyses were performed using Statistical Package for Social Science (SPSS) version 20. The descriptive statistics of mean, standard deviation and percentages were calculated for the entire sample. Chi-square test was used to examine differences in the prevalence of different categorical variables. The differences between means were tested by independent samples t-test and one-way ANOVA. The odds ratio (OR) and the confidence interval (CI) for the presence of MetSat, different PA levels were calculated. P value less than 0.05 was considered as statistically significant.

**Ethical issues**: The study protocol was approved by the Ethics Committee of Tehran University of Medical Sciences (Code: IR.TUMS.REC.1394.58) and by the Palestinian Health Research Council (Helsinki Ethical Committee of Research PHRC/HC/60/15). Furthermore, written informed consent was obtained from the study participants and concerned bodies.

Results
=======

A total of 1200 patients with T2DM aged 20 to 64 years old (59.8% females, 40.2% males) were included in this study. [Table 1](#T1){ref-type="table"} shows the characteristics of the study population by sex in relation to the presence of MetS and its absence (According to IDF definition). Our findings demonstrate that the mean age for males with MetS was 55.3±6.9 vs. 42.6±10.1 in the non-MetS group; the mean age for females with MetS is 55.5±6.9 and 38.0±9.6 in the non-MetS group. In addition, [Table 1](#T1){ref-type="table"} shows that for the following risk factors (Age, BMI, central obesity, high BP, high TGs and low HDL-c), the difference was statistically significant in both sexes (P value \< 0.05). Then, we examined the relationship between MetS and medical history factors ([Table 2](#T2){ref-type="table"}). A significant inverse association was found between diabetes duration, BMI and the MetS (P value \< 0.05). In addition, our findings showed that 48.4% of the patients with MetS received diabetes care instructions, all patients (100%) used diabetes medications, 91.4% of the patients with MetS used pills and nsulin injections, 54.9% were smokers, no patients consumed alcohol and most of female patients with MetS (89.5%) were post-menopause. For these risk factors, the difference was statistically significant between T2DM patients with and without MetS (P value \< 0.05). In addition, we concluded in [Table 3](#T3){ref-type="table"} that the mean weekly metabolic energy expenditure expressed as MET/wk for males with MetS was 905.2±9 vs. 2729.8±1 in males without MetS. The mean for females with MetS was 710.6±1 MET/wk and 2293.2±1 MET/wk in females without MetS. And the difference was statistically significant between the MetS and non-MetS groups in both sexes (P value \< 0.05, T value = 5.903). The obtained results showed that the mean energy expenditure, which includes the body weight in its formula and is expressed in kcal/wk for males with MetS, was 1413.7±1 vs. 3465.3±2 in males without MetS. The mean for females with MetS is 1028.1±1 kcal/wk and 2564.3±1 kcal/wk in females without MetS and the difference was statistically significant between the MetS and non-MetS groups in both sexes (P value \< 0.05, T value = 7.041). Also, we found a significant inverse association between PA levels (IA, SA and VA) and the incidence of MetS in both sexes (P value \< 0.05). Furthermore, our findings demonstrated that there was a significant inverse association between PA levels and anthropometric measurements such as BMI and WC for males and females (P value \< 0.05) as shown in [Table 4](#T4){ref-type="table"}. In addition, we found a significant association between PA levels and TGs (P value \< 0.01), HDL-c (P value \< 0.01) and BP (P value \< 0.01) in males and females. With respect to FPG, we found a significant association between PA levels and FPG in males (P value \< 0.05), but in females, the difference did not reach a statistical significant level (P value = 0.360). Also, we computed the OR and the CI of the MetS atdifference PA levels (IA, SA & VA) ([Table 5](#T5){ref-type="table"}). Our findings demonstrated that 93.7% of IA patients had MetS OR .048 CI 95% (.03--.072), 66.4% of SA patients had MetS OR .787 CI 95% (.59--1.03) and 23.5% of VA patients had MetS OR 15.9 CI 95% (11.8--21.3). Finally, we examined the relationship between PA levels (IA, SA and VA) and diabetes complications (Eye problems, kidney problems, protein in urine, heart problems, extremities problems and neurological problems). [Table 6](#T6){ref-type="table"} shows that there was a significant association between PA levels and diabetes complications (P value \< 0.05). Finally, a significant association was found between diabetes complications (Eye problems, kidney problems, protein in urine, heart problems, extremities problems and neurological problems) and the prevalence of MetS in our study population (P value \< 0.05).

###### 

Characteristics of the study population by sex in relation to the presence of MetS or its absence (According to IDF definition).

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Parameters                                                 Total No. of\   Males         *P*          Females   *P*                         
                                                             Subjects\                                                                        
                                                             (n=1200)                                                                         
  ---------------------------------------------------------- --------------- ------------- ------------ --------- ------------- ------------- ------
  Age (years)                                                49.74±11.07     55.3±6.9      42.6±10.1    .001      55.5±6.9      38.0±9.6      .001

  BMI (kg/m^2^)                                              30.22±6.28      31.1±4.5      25.0±3.6     .001      34.2±5.9      25.4±3.4      .001

  Central obesity                                            985 (82.08%)    258 (100%)    57 (25.4%)   .001      490 (100%)    180 (78.9%)   .001

  High BP                                                    771 (64.25%)    250 (96.8%)   39 (17.4%)   .001      481 (98.1%)   1 (0.4%)      .001

  High triglycerides                                         504 (42%)       154 (59.6%)   8 (3.5%)     .001      341 (69.5%)   1 (0.4%)      .001

  Low HDL-c                                                  487 (40.58%)    138 (53.4%)   8 (3.5%)     .001      340 (69.3%)   1 (0.4%)      .001

                                                                                                                                              

  In our study, all participants previously diagnosed T2DM                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------

Central obesity was defined as waist circumference ≥ 94 cm in men and ≥ 80 cm in women. High blood pressure was ≥ 130/85 mmHg or treatment of previously diagnosed hypertension. High triglyceride was ≥150 mg/dl or specific treatment for this lipid abnormality. Low high-density lipoprotein cholesterol was \<40 mg/dl in males and \<50 mg/dl in females or specific treatment for this lipid abnormality.

The differences between means were tested by using independent sample t test. Descriptive statistics, Crosstabs, the chi-square test were used to examine difference in the prevalence of different categorical variables. P value less than 0.05 was considered as statistically significant.

###### 

Distribution of the study population by medical history variables in relation to the presence of MetS or its absence.

  Medical history              Metabolic syndrome   Total   *P*                               
  ---------------------------- -------------------- ------- ------ ----- ------- ------ ----- ------
  Diabetic duration            Less than five       72      22.8   244   77.2    316    100   
                               Five to ten          274     63.1   160   36.9    434    100   .001
                               More than ten        402     89.3   48    10.7    450    100   
  BMI category                 Under weight         0       0.0    7     100.0   7      100   
                               Healthy weight       36      13.8   225   86.2    261    100   
                               Over weight          186     50.8   180   49.2    366    100   .001
                               Obesity              526     92.9   40    7.1     566    100   
  Family history of diabetes   Yes                  640     62.7   380   37.3    1020   100   
                               No                   108     60.0   72    40.0    180    100   .483
  Received DM care             Yes                  278     48.4   296   51.6    574    100   
  instructions                 No                   470     75.1   156   24.9    626    100   .001
  Use DM medications           Yes                  748     62.3   452   37.7    1200   100   \-
  Type of diabetes             Diabetes pills       243     49.5   248   50.5    491    100   
  medications used             Insulin injections   431     68.6   197   31.4    628    100   .001
                               Pills & injections   74      91.4   7     8.6     81     100   
  Smoking                      Yes                  89      54.9   73    45.1    162    100   
                               No                   659     63.5   379   36.5    1038   100   .001
  Consume alcohol              No                   748     62.3   452   37.7    1200   100   \-
  Females menopausal status    Premenopausal        40      18.6   175   81.4    215    100   
                               Postmenopausal       450     89.5   53    10.5    503    100   .001
                               Male                 258     53.5   224   46.5    482    100   

Descriptive statistics, Crosstabs, the chi-square test was used to examine difference in the prevalence of different categorical variable. P value less than 0.05 was considered as statistically significant.

###### 

Distribution of weekly energy expenditure, PA levels and weekly PA duration by sex in relation to the presence of MetS or its absence.

  --------------------------------------------------------------------------------------------------------------------------------
  Parameters                          Total No. of\   Males         *P*           Females       *P*                         
                                      Subjects\                                                                             
                                      (n=1200)                                                                              
  ----------------------------------- --------------- ------------- ------------- ------------- ------------- ------------- ------
  Weekly energy expenditure                                                                                                 

  MET/wk                              1430.1±1519.2   905.2±965     2729.8±1762   .001          710.6±1054    2293.2±1357   .001

  Kcal/wk                             1857.8±1965.7   1413.7±1766   3465.3±2352   .001          1028.1±1483   2564.3±1393   .001

  Physical activity levels (MET/wk)                                                                                         

  IA (≤ 600)                          476 (39.6%)     128 (86.5%)   20 (13.5%)    .001          318 (97.0%)   10 (3.0%)     .001

  SA (601 to 1500)                    307 (25.5%)     88 (67.7%)    42 (32.3%)    116 (65.5%)   61 (34.5%)                  

  VA (≥1500)                          417 (34.75%)    42 (20.6%)    162 (79.4%)   56 (26.3%)    157 (73.7%)                 
  --------------------------------------------------------------------------------------------------------------------------------

MET/wk: Weekly energy expenditure in metabolic equivalents per wk.

Kcal/wk: Weekly energy expenditure in kilocalories = MET \* weight (kg) / 60.

IA= Insufficiently Active; SA= Sufficiently Active; VA= Very Active.

The differences between mean were tested by using independent sample T test and one-way ANOVA. P value less than 0.05 was considered as statistically significant.

###### 

Risk factors for MetS at different PA levels for males and females.

  Parameters      Males        *P*          Females      *P*                                           
  --------------- ------------ ------------ ------------ ------ ------------ ------------ ------------ ------
                  Mean ± SD    Mean ± SD    Mean ± SD           Mean ± SD    Mean ± SD    Mean ± SD    
  BMI (kg/m^2^)   31.0±4.6     28.8±4.7     25.9±4.6     .001   35.1±6.0     30.5±5.2     26.7±5.1     .001
  WC (cm)         110.4±12.3   104.1±13.2   92.6±12.1    .001   117.2±13.7   105.3±15.0   93.1±16.2    .001
  FPG (mg/dl)     171.4±29.1   171.3±29.1   164.7±24.9   .031   169.9±33.4   173.0±27.9   168.7±26.4   .360
  TGs (mg/dl)     188.2±57.5   157.9±48.9   127.1±20.7   .001   193.7±50.6   150.4±43.8   131.4±43.2   .001
  HDL-c(mg/dl)    37.9±6.1     41.8±5.6     46.1±4.2     .001   41.1±7.2     49.5±7.6     53.5±6.2     .001
  SBP (mmHg)      138.9±9.6    134.3±10.2   122.3±8.2    .001   141.2±9.0    130.7±11.0   121.7±9.9    .001
  DBP (mmHg)      87.4±6.0     86.0±5.5     79.2±5.6     .001   89.3±5.7     83.2±7.2     78.3±6.9     .001

Activity level category measured in metabolic equivalents per week (MET/wk): IA= insufficiently active (≤600 MET/wk); SA= sufficiently active (601 to 1500 MET/wk); and VA= very active (≥1500 MET/wk).

BMI= body mass index; WC= waist circumference; FPG= fasting plasma glucose; TGs= triglycerides; HDL-c= high-density lipoprotein-cholesterol; SBP= systolic blood pressure; DBP= diastolic blood pressure.

The differences between mean were tested by using independent sample T test and one-way ANOVA. P value less than 0.05 was considered as statistically significant.

###### 

Odds ratios of having MetS at different PA levels (According to IDF definition).

  ------------------------------------------------------------------------------------------------------------------------
  Parameters                                 MetS   Total         *P*           OR\                    
                                                                                (95%CI)                
  ------------------------------------------ ------ ------------- ------------- --------- ----- ------ -------------------
  Insufficiently active (≤ 600 MET/wk)       Yes    446 (93.7%)   30 (6.3%)     476       100          .048 (.03--.072)

                                             No     302 (41.7%)   422 (58.3%)   724       100          

  Sufficiently active (601 to 1500 MET/wk)   Yes    204 (66.4%)   103 (33.6%)   307       100   .084   .787 (.59--1.03)

                                             No     544 (60.9%)   349 (39.1%)   893       100          

  Very active (≥ 1500 MET/wk)                Yes    98 (23.5%)    319 (76.5%)   417       100          

                                             No     650 (83.0%)   133 (17.0%)   783       100   .001   15.9 (11.8--21.3)
  ------------------------------------------------------------------------------------------------------------------------

MET/wk: metabolic equivalents per week

The presence of MetS at different PA levels was calculated, using odds ratio and confidence interval of each risk factor. P value less than 0.05 was considered as statistically significant.

###### 

Distribution of the study population by diabetes complications variables in relation to the presence of MetS or its absence and at different PA levels.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Diabetes\       Activity level category   *P*   Metabolic syndrome   Total   *P*                                                               
  complications                                                                                                                                  
  --------------- ------------------------- ----- -------------------- ------- ------ ----- ------ ------ ----- ------ ----- ------ ------ ----- ------
  Eye problems    Yes                       348   73.1                 161     52.4   185   44.4          518   74.6   176   25.4   694    100   

                  No                        128   26.9                 146     47.6   232   55.6   .001   230   45.5   276   54.5   506    100   .001

  Kidney          Yes                       89    18.7                 23      7.5    18    4.3           122   93.8   8     6.2    130    100   

  problems        No                        387   81.3                 284     92.5   399   95.7   .001   626   58.5   444   41.5   1070   100   .001

  Protein in      Yes                       361   75.8                 159     51.8   118   28.3          512   80.3   126   19.7   638    100   

  urine           No                        115   24.2                 148     48.2   299   71.7   .001   236   42.0   326   58.0   562    100   .001

  Heart           Yes                       59    12.4                 14      4.6    14    3.4           84    96.6   3     3.4    87     100   

  problems        No                        417   87.6                 293     95.4   403   96.6   .001   664   59.7   449   40.3   1113   100   .001

  Extremities     Yes                       187   39.3                 54      17.6   23    5.5           235   89.0   29    11.0   264    100   

  problems        No                        289   60.7                 253     82.4   394   94.5   .001   513   54.8   423   45.2   936    100   .001

  Neurological    Yes                       467   98.1                 286     93.2   353   84.7          721   65.2   385   34.8   1106   100   

  problems        No                        9     1.9                  21      6.8    64    15.3   .001   27    28.7   67    71.3   94     100   .001
  -----------------------------------------------------------------------------------------------------------------------------------------------------

Activity level category measured in metabolic equivalents per week (MET/wk): IA= insufficiently active (≤600 MET/wk); SA= sufficiently active (601 to 1500 MET/wk); and VA= very active (≥1500 MET/wk).

Descriptive statistics, Crosstabs, the chi-square test was used to examine difference in the prevalence of different categorical variable. P value less than 0.05 was considered as statistically significant.

Discussion
==========

To the best of our knowledge, this is the first report, which describes the relationship between PA and MetS among T2DM patients in Gaza Strip, Palestine. The main findings of this study indicate that low levels of PA are associated with increased prevalence of MetS. Many previous studies suggest that we should expect a higher number of IA individuals in the MetS patients ([@R18],[@R19]). Katzmarzyk et al. ([@R20]) found that PA reduced the risk for MetS among black and white women and men in Canada. Other studies have consistently found an inverse association between PA and the lack of MetS among middle-aged white men in the United States ([@R21]), middle-aged and older men and women in China ([@R22]) and adult men and women in Australia ([@R23]). Moreover, Panagiotakos et al. ([@R24]) evaluated the association between PA and the prevalence of MetS among Greek adults. The author showed that even light to moderate leisure time PA was associated with a considerable reduction in the prevalence of MetS in 3042 men and women from the general population. The results of this study support these findings. In addition, according to the IPAQ scoring protocol, the patients were classified based on their weekly energy expenditure as follows: IA, SA and VA ([@R17]). Roberta et al. ([@R25]) used the same method to investigate the levels of PA in patients with and without MetS. The author concluded that patients with MetS presented the same levels of PA as the individuals who did not have MetS. Our study also showed a significant inverse association between PA levels and anthropometric measurements such as BMI and WC for both sexes. Ohkawara et al. ([@R26]) in a systematic review found a dose-response effect between an increase in PA and decrease in visceral fat. Rennie et al. ([@R27]) similarly found an inverse relationship between PA and BMI and WC. Panagiotakos et al. ([@R24]) found that MetS subjects who were sedentary, both males and females, were having high WC compared to them with moderate PA. According to BMI classification results, obesity was more prevalent in subjects having sedentary PA compared to moderate physically active MetS subjects. Moreover, we found a significant association between PA levels and TGs, HDL-c and BP in both sexes (P value \< 0.05). The literature strongly supports the benefits of exercise and PA in the prevention of MetS and T2DM. Increased PA promotes weight loss, improves insulin sensitivity, increases HDL-c levels, lowers TGs levels and prevents hypertension ([@R28],[@R29],[@R30],[@R31]), which are considered the main components of MetS. Finally, according to the results of this study, there were significant inverse associations between PA and diabetes complications including eye problems, kidney problems, protein in urine, heart problems, extremities problems and neurological problems among T2DM patients. Many previous studies show that a regular PA may prevent or delay diabetes and its complications ([@R32],[@R33],[@R34]). Moreover, the available data show that a higher degree of diabetes complication is associated with lower PA levels ([@R35],[@R36]). The main limitations of our study include its cross-sectional design, the fact that the causal relationship could not be fully determined and the possibility of recall bias by using questionnaire-based assessment of PA. The main strength of this study was being the first study, which describes the relationship between PA and MetS among T2DM patients in Gaza Strip, Palestine, and its large sample size.

We conclude that low levels of PA are associated with increased prevalence of MetS. In addition, insufficiently active patients had a high percentage of diabetes complications among T2DM patients in Gaza Strip, Palestine.
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